A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination with ACP-196 in Subjects with Previously Untreated Metastatic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2016
At a glance
- Drugs Acalabrutinib (Primary) ; Gemcitabine; Paclitaxel
- Indications Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Acerta Pharma
- 23 Jun 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2017.
- 20 Apr 2016 Status changed from recruiting to discontinued.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.